Literature DB >> 25702829

Designing new analogs for streamlining the structure of cytotoxic lamellarin natural products.

Kassrin Tangdenpaisal1, Rattana Worayuthakarn, Supatra Karnkla, Poonsakdi Ploypradith, Pakamas Intachote, Suchada Sengsai, Busakorn Saimanee, Somsak Ruchirawat, Montakarn Chittchang.   

Abstract

Despite the therapeutic potential of marine-derived lamellarin natural products, their preclinical development has been hampered by their lipophilic nature, causing very poor aqueous solubility. In order to develop more drug-like analogs, their structure was streamlined in this study from both the cytotoxic activity and lipophilicity standpoints. First, a modified total synthetic route was successfully devised to construct a library of 59 systematically designed lamellarin analogs, which were then subjected to cytotoxicity and log P determinations. Along with the 25 first-generation lamellarins previously synthesized in our laboratory, the structure-activity and structure-lipophilicity relationships were extensively evaluated. Our results clearly indicated the additional structural requirements around the lamellarin skeleton which, when combined with those reported previously, can provide invaluable guidance for further modifications to increase the aqueous solubility of these compounds.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cytotoxicity; lamellarins; lipophilicity; pyrrole alkaloids; structure-activity relationships

Mesh:

Substances:

Year:  2015        PMID: 25702829     DOI: 10.1002/asia.201403361

Source DB:  PubMed          Journal:  Chem Asian J        ISSN: 1861-471X


  1 in total

1.  Highly diastereoselective construction of novel dispiropyrrolo[2,1-a]isoquinoline derivatives via multicomponent 1,3-dipolar cycloaddition of cyclic diketones-based tetrahydroisoquinolinium N-ylides.

Authors:  Sarra Boudriga; Saoussen Haddad; Moheddine Askri; Armand Soldera; Michael Knorr; Carsten Strohmann; Christopher Golz
Journal:  RSC Adv       Date:  2019-04-09       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.